Alphatec Reports Q3 2026 Revenue Growth Amid Lower Biologics Attachment and Revised Guidance
Alphatec Holdings, Inc. (ATEC) reported third-quarter revenue of $221 million, a 13% year-over-year increase driven primarily by a 17% growth in surgical hardware and a record 25% increase in new surgeon adoption. Despite these strengths, the company faced headwinds from a decline in biologics revenue due to increased competition and lower attachment rates, as well as market softness in thoracolumbar procedure volumes. In response to these challenges, Alphatec has revised its full-year 2026 revenue guidance downward to $862 million. While the company is navigating supply constraints in international markets and a slight decline in revenue per case, it maintained its adjusted EBITDA margin targets and reported an expansion in non-GAAP gross margins to 71.9% due to improved inventory efficiency.
Tickers: $ATEC
Topics: Biologics EBITDA Financial Guidance Revenue Growth Surgical Hardware
Read the full article at Motley Fool
Part of the story Sunrun Reports Q3 2026 Revenue Growth Amidst Lowered Cash Generation Guidance (25 articles)